Therapeutic CD154 antibody for lupus: promise for the future?
G Kelsoe - The Journal of clinical investigation, 2003 - Am Soc Clin Investig
The Journal of clinical investigation, 2003•Am Soc Clin Investig
Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disease
characterized by the production of pathogenic autoantibodies. A new study demonstrates
that passive antibody specific for the TNF family member, CD154, ameliorates disease by
reducing levels of self-reactive antibody in the serum. This study demonstrates a substantial
potential for anti-CD154 antibody in the treatment of humoral autoimmunity.
characterized by the production of pathogenic autoantibodies. A new study demonstrates
that passive antibody specific for the TNF family member, CD154, ameliorates disease by
reducing levels of self-reactive antibody in the serum. This study demonstrates a substantial
potential for anti-CD154 antibody in the treatment of humoral autoimmunity.
Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disease characterized by the production of pathogenic autoantibodies. A new study demonstrates that passive antibody specific for the TNF family member, CD154, ameliorates disease by reducing levels of self-reactive antibody in the serum. This study demonstrates a substantial potential for anti-CD154 antibody in the treatment of humoral autoimmunity.
The Journal of Clinical Investigation